Greenland Mines (NASDAQ: GRML) has announced a series of strategic moves as it pivots to become a pure-play rare earths and critical minerals company. The company will spin off its biotechnology division in the fourth quarter of 2026, following Nasdaq's formal approval of its application related to the March 2026 transaction, which resolves prior deficiencies and brings the company into full compliance with listing requirements. This corporate restructuring underscores the company's commitment to its mining operations, particularly its flagship Sarfartoq project in Greenland.
The acquisition of the Sarfartoq project was completed on Sept. 1, following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit revealed a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The project is expected to produce neodymium-praseodymium (NdPr) oxide, a critical component in permanent magnets used in electric vehicles and wind turbines. Planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This positions Greenland Mines to play a significant role in the global supply chain for rare earth elements, especially as Western nations seek to reduce dependence on Chinese exports.
In addition to the Sarfartoq acquisition, the company is advancing its Skaergaard palladium-gold-platinum project in southeast Greenland. The company's strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision. This corridor aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure, enhancing supply chain security for critical minerals.
To support these initiatives, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins will join the board. Hawkins's experience is expected to be instrumental as the company advances Sarfartoq and Skaergaard and navigates the capital markets.
The decision to spin off the biotech division, which includes Klotho's KLTO-202 for ALS, allows the company to focus on its core mining assets. This move is likely to be well-received by investors seeking pure-play exposure to the critical minerals sector, which is a strategic priority for many governments. The Sarfartoq project's robust economics and the growing demand for NdPr oxide make Greenland Mines a notable player in the rare earth market.
For more details on the full press release, visit https://ibn.fm/QN1U9. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
